Promoting access to biosimilars: a public−private partnership model for biosimilar development in underserved populations
Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 2
Abstract
Biologicals represent the future of pharmaceutical treatments and innovation. Yet, emerging and developing markets lack access to these often essential medicines. Biosimilar development represents a potential solution to this problem, by offering lower cost and improved access, but is also associated with patient safety issues. In order to synergize these divergent challenges, targeted public−private partnerships that bring together shared goals and resources of the public sector, global firms, and local manufacturers need to be explored. Crucial to their success will be equitable intellectual property rights management and coordination and collaboration with effective governance and incentives.
Authors and Affiliations
Timothy Ken Mackey, Bryan A Liang
Keywords
Related Articles
- EP ID EP355162
- DOI 10.5639/gabij.2012.0102.018
- Views 146
- Downloads 0
IAPO launched the Patient-Centred Healthcare Indicators Review
In October 2012, the International Alliance of Patients’ Organizations (IAPO) launched its final Patient-Centred Healthcare Indicators Review and accompanying consultation report [1]. The review forms the initial stage o...
Oncologists urged to embrace biosimilars to help control spiralling costs of cancer care
Oncologists urged to embrace biosimilars to help control spiralling costs of cancer care Oncologists have been urged to embrace biosimilar drug substitution to help control the spiralling costs of cancer care. However, t...
What to look forward to in GaBI Journal, 2013, Issue 2
The first of two Letters to the Editor is from Ms Gaspani and Ms Milani expressing their concerns about the lack of clear regulatory guidelines for approval of liposomal generic formulations. Liposomal products are only...
Health professionals in the risk communication process on counterfeit medicines
Communication is a key component in the fight against counterfeit medicines affecting the lives of patients. Two types of risk communication should be distinguished: pro-active and reactive. Reactive communication can be...
Reference price systems: stakeholder dialogue and involvement
Dylst et al. provide a detailed overview about the characteristics of reference price systems in Europe and discuss their possible impact. The role of stakeholders in the implementation of this policy measure requires fu...